Toll Free: 1-888-928-9744

Hemostats - Medical Devices Pipeline Assessment, 2016

Published: Mar 11, 2016 | Pages: 118 | Publisher: GlobalData | Industry: Medical Devices | Report Format: Electronic (PDF)

Hemostats - Medical Devices Pipeline Assessment, 2016

Summary

GlobalData's Medical Devices sector report, "Hemostats - Medical Devices Pipeline Assessment, 2016" provides an overview of Hemostats currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Hemostats pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Hemostats under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Hemostats and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons To Buy

The report enables you to - 
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Hemostats under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product's current stage of development, territory and estimated launch date
 Table of Contents
1 Table of Contents 2 1.1 List of Tables 5 1.2 List of Figures 8 2 Introduction 9 2.1 Hemostats Overview 9 3 Products under Development 10 3.1 Hemostats - Pipeline Products by Stage of Development 10 3.2 Hemostats - Pipeline Products by Segment 11 3.3 Hemostats - Pipeline Products by Territory 12 3.4 Hemostats - Pipeline Products by Regulatory Path 13 3.5 Hemostats - Pipeline Products by Estimated Approval Date 14 3.6 Hemostats - Ongoing Clinical Trials 15 4 Hemostats - Pipeline Products under Development by Companies 16 4.1 Hemostats Companies - Pipeline Products by Stage of Development 16 4.2 Hemostats - Pipeline Products by Stage of Development 18 5 Hemostats Companies and Product Overview 20 5.1 3-D Matrix, Ltd. Company Overview 20 5.1.1 3-D Matrix, Ltd. Pipeline Products & Ongoing Clinical Trials Overview 20 5.2 Advanced Medical Solutions Group plc Company Overview 23 5.2.1 Advanced Medical Solutions Group plc Pipeline Products & Ongoing Clinical Trials Overview 23 5.3 Anika Therapeutics, Inc. Company Overview 31 5.3.1 Anika Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 31 5.4 Arch Therapeutics Inc. Company Overview 33 5.4.1 Arch Therapeutics Inc. Pipeline Products & Ongoing Clinical Trials Overview 33 5.5 Argon Medical Devices Inc. Company Overview 37 5.5.1 Argon Medical Devices Inc. Pipeline Products & Ongoing Clinical Trials Overview 37 5.6 Baxter International Inc. Company Overview 38 5.6.1 Baxter International Inc. Pipeline Products & Ongoing Clinical Trials Overview 38 5.7 Beth Israel Deaconess Medical Center, Inc. Company Overview 43 5.7.1 Beth Israel Deaconess Medical Center, Inc. Pipeline Products & Ongoing Clinical Trials Overview 43 5.8 Biomedica Management Corporation Company Overview 44 5.8.1 Biomedica Management Corporation Pipeline Products & Ongoing Clinical Trials Overview 44 5.9 Biom'Up SAS Company Overview 48 5.9.1 Biom'Up SAS Pipeline Products & Ongoing Clinical Trials Overview 48 5.10 Cellphire, Inc. Company Overview 49 5.10.1 Cellphire, Inc. Pipeline Products & Ongoing Clinical Trials Overview 49 5.11 Covalent Medical, Inc. (Inactive) Company Overview 52 5.11.1 Covalent Medical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 52 5.12 Covalon Technologies Ltd. Company Overview 53 5.12.1 Covalon Technologies Ltd. Pipeline Products & Ongoing Clinical Trials Overview 53 5.13 CryoLife, Inc. Company Overview 56 5.13.1 CryoLife, Inc. Pipeline Products & Ongoing Clinical Trials Overview 56 5.14 Endomedix Incorporated Company Overview 60 5.14.1 Endomedix Incorporated Pipeline Products & Ongoing Clinical Trials Overview 60 5.15 Entegrion, Inc. Company Overview 62 5.15.1 Entegrion, Inc. Pipeline Products & Ongoing Clinical Trials Overview 62 5.16 Ethicon, Inc. Company Overview 63 5.16.1 Ethicon, Inc. Pipeline Products & Ongoing Clinical Trials Overview 63 5.17 Floralis S.A.S. Company Overview 64 5.17.1 Floralis S.A.S. Pipeline Products & Ongoing Clinical Trials Overview 64 5.18 Gamma Therapeutics, Inc. Company Overview 65 5.18.1 Gamma Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 65 5.19 Haemostatix Limited Company Overview 66 5.19.1 Haemostatix Limited Pipeline Products & Ongoing Clinical Trials Overview 66 5.20 Hemostasis, LLC Company Overview 69 5.20.1 Hemostasis, LLC Pipeline Products & Ongoing Clinical Trials Overview 69 5.21 KeraNetics, LLC Company Overview 71 5.21.1 KeraNetics, LLC Pipeline Products & Ongoing Clinical Trials Overview 71 5.22 LifeBond Ltd. Company Overview 72 5.22.1 LifeBond Ltd. Pipeline Products & Ongoing Clinical Trials Overview 72 5.23 Remedium Technologies Inc. Company Overview 75 5.23.1 Remedium Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 75 5.24 Rice University Company Overview 76 5.24.1 Rice University Pipeline Products & Ongoing Clinical Trials Overview 76 5.25 Samyang Biopharmaceuticals Corporation Company Overview 78 5.25.1 Samyang Biopharmaceuticals Corporation Pipeline Products & Ongoing Clinical Trials Overview 78 5.26 Sanofi Company Overview 80 5.26.1 Sanofi Pipeline Products & Ongoing Clinical Trials Overview 80 5.27 Sea Run Holdings Inc. Company Overview 82 5.27.1 Sea Run Holdings Inc. Pipeline Products & Ongoing Clinical Trials Overview 82 5.28 St Teresa Medical, Inc. Company Overview 83 5.28.1 St Teresa Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 83 5.29 Suneris Technologies, Inc. Company Overview 87 5.29.1 Suneris Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 87 5.30 The Medicines Company Company Overview 88 5.30.1 The Medicines Company Pipeline Products & Ongoing Clinical Trials Overview 88 5.31 Therus Corporation Company Overview 90 5.31.1 Therus Corporation Pipeline Products & Ongoing Clinical Trials Overview 90 5.32 Xcede Technologies, Inc. Company Overview 91 5.32.1 Xcede Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 91 6 Hemostats- Recent Developments 92 6.1 Feb 18, 2016: Genelife Enters into Licensing Agreement with 3-D Matrix Europe 92 6.2 Feb 17, 2016: Z-Medica Receives Expanded CE Mark for QuikClot 92 6.3 Jan 21, 2016: United Health Products Announces Optimal Government Services as UHP's Exclusive Government Distributor 92 6.4 Dec 16, 2015: Arch Therapeutics Receives Clearance to Initiate Clinical Trial in Europe 93 6.5 Dec 09, 2015: Arsenal Medical Secures Funding from U.S. Army to Advance ResQFoam Trauma Product through Regulatory Approval 93 6.6 Dec 04, 2015: Change in B. Braun Management Board 94 6.7 Dec 01, 2015: Arch Therapeutics Reports Significant Wound Healing Results in Pre-Clinical Safety Study with AC5 Surgical Hemostatic Device 94 6.8 Nov 17, 2015: CryoLife Announces Resolution of PerClot Litigation with Medafor 95 6.9 Oct 28, 2015: United Health Products' HemoStyp Now Available Through Henry Schein 95 6.10 Oct 22, 2015: CoAg Medical And Lou Ferrigno Announce StopsBleeding Product Launch 95 6.11 Oct 20, 2015: Vascular Solutions Reports Third Quarter Results-2015 96 6.12 Sep 08, 2015: Arch Therapeutics Obtains Additional Positive Safety Data for AC5 Surgical Hemostatic Device in Preclinical Toxicity Test of Sensitization 98 6.13 Aug 24, 2015: United Health Products Announces School Health as a Distributor 99 6.14 Aug 18, 2015: Dynasil Announces Xcede Technologies' Patent Application for Novel All-in-One Patch 99 6.15 Aug 05, 2015: LifeBond Raises USD27 Million in Series D Financing 99 6.16 Aug 04, 2015: Suneris CEO to Present VETIGEL at White House Demo Day 99 6.17 Jul 21, 2015: Vascular Solutions Reports Second Quarter Results 100 6.18 Jul 15, 2015: Remedium Technologies Receives FDA Clearance for Hemogrip Technology to Help Stop Bleeding 102 6.19 Jul 14, 2015: St. Teresa Medical Announces First Patient Enrolled in SURGICLOT Clinical Trial in U.K 102 6.20 Jun 26, 2015: Suneris Introduces VETIGEL as a New Wound Care Solution for Veterinarians 103 6.21 Jun 15, 2015: OxySure Systems Enters into Distribution Agreement with Z-Medica 103 6.22 Jun 09, 2015: Arch Therapeutics Obtains Additional Safety Data for Its AC5 Surgical Hemostatic Device in Successful Preclinical Toxicity Test 103 6.23 May 13, 2015: DuBiotech Welcomes Germany's B.Braun 104 6.24 Apr 30, 2015: The Medicines Company Announces FDA Approval of RAPLIXA (Fibrin Sealant), the First and Only Powdered Fibrin Sealant Ready-to-Use for Mild to Moderate Surgical Bleeding 104 6.25 Apr 28, 2015: CryoLife Begins Patient Enrolment In PerClot IDE Clinical Trial 105 6.26 Apr 21, 2015: Vascular Solutions Reports First Quarter Results 106 6.27 Apr 16, 2015: Arch Therapeutics' AC5 Compared Favorably vs. Commercially Available Combination Hemostat in Animal Study 108 6.28 Apr 14, 2015: Arch Therapeutics Announces Favorable Preclinical Data From an Independent Study of AC5 Surgical Hemostatic Device Versus a Popular Fibrin Sealant 109 6.29 Apr 07, 2015: United Health Products Announces Laboratory Test Results 110 6.30 Apr 01, 2015: Z-Medica Announces QuikClot Products Approved in California 110 6.31 Mar 27, 2015: B. Braun Group increases sales and earnings 111 6.32 Mar 25, 2015: Arch Therapeutics Announces Favorable Preclinical Data from an Independent Study of AC5 Surgical Hemostatic Device Versus a Popular Cellulose-Based Hemostatic Agent 112 6.33 Mar 23, 2015: Arch Therapeutics Announces Positive Safety Results for AC5 Surgical Hemostatic Device in Preclinical Toxicity Studies 113 6.34 Mar 13, 2015: Withdrawal of Application for the Approval of the Hemostat (TDM-621) 113 6.35 Mar 12, 2015: CryoLife Provides Update on PerClot Litigation 113 7 Appendix 115 7.1 Methodology 115 7.2 About GlobalData 117 7.3 Contact Us 118 7.4 Disclaimer 118
List of Tables
Table 1: Hemostats - Pipeline Products by Stage of Development 10 Table 2: Hemostats - Pipeline Products by Segment 11 Table 3: Hemostats - Pipeline Products by Territory 12 Table 4: Hemostats - Pipeline Products by Regulatory Path 13 Table 5: Hemostats - Pipeline Products by Estimated Approval Date 14 Table 6: Hemostats - Ongoing Clinical Trials 15 Table 7: Hemostats Companies - Pipeline Products by Stage of Development 16 Table 8: Hemostats - Pipeline Products by Stage of Development 18 Table 9: 3-D Matrix, Ltd. Pipeline Products & Ongoing Clinical Trials Overview 20 Table 10: PuraStat Hemostat - Product Status 21 Table 11: PuraStat Hemostat - Product Description 21 Table 12: TDM-511 - Product Status 22 Table 13: TDM-511 - Product Description 22 Table 14: Advanced Medical Solutions Group plc Pipeline Products & Ongoing Clinical Trials Overview 23 Table 15: Antibiotic Hemostat - Product Status 24 Table 16: Antibiotic Hemostat - Product Description 24 Table 17: GENTA-COLL Resorb - Product Status 25 Table 18: GENTA-COLL Resorb - Product Description 25 Table 19: GENTA-FOIL Resorb - Product Status 26 Table 20: GENTA-FOIL Resorb - Product Description 26 Table 21: KOLLAGEN resorb - Product Status 27 Table 22: KOLLAGEN resorb - Product Description 27 Table 23: RESORBA CELL Fibrillar - Product Status 28 Table 24: RESORBA CELL Fibrillar - Product Description 28 Table 25: RESORBA CELL forte - Product Status 29 Table 26: RESORBA CELL forte - Product Description 29 Table 27: RESORBA CELL standard - Product Status 30 Table 28: RESORBA CELL standard - Product Description 30 Table 29: Anika Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 31 Table 30: Hemostatic Patch - Product Status 32 Table 31: Hemostatic Patch - Product Description 32 Table 32: Arch Therapeutics Inc. Pipeline Products & Ongoing Clinical Trials Overview 33 Table 33: AC5 Surgical Hemostatic Device - Product Status 34 Table 34: AC5 Surgical Hemostatic Device - Product Description 34 Table 35: Arch Therapeutics Inc. - Ongoing Clinical Trials Overview 35 Table 36: AC5 Surgical Hemostatic Device - AC5 Surgical Hemostatic Device Clinical Trial in Europe 36 Table 37: Argon Medical Devices Inc. Pipeline Products & Ongoing Clinical Trials Overview 37 Table 38: Hemaseel Thrombin Haemostatic Agent - Product Status 37 Table 39: Hemaseel Thrombin Haemostatic Agent - Product Description 37 Table 40: Baxter International Inc. Pipeline Products & Ongoing Clinical Trials Overview 38 Table 41: Hemopatch - Product Status 39 Table 42: Hemopatch - Product Description 39 Table 43: Baxter International Inc. - Ongoing Clinical Trials Overview 40 Table 44: Hemopatch - A Phase II Prospective, Single Blinded, Randomized Trial of Hemopatch Compared to Standard Techniques to Achieve Air Leak Control After Complex Thoracic Surgical Procedures on High Risk Population for Prolonged Air Leak (> 5 Days - PAL) 41 Table 45: Hemopatch - A Prospective Randomized Trial of Hemopatch Versus No Hemopatch for the Intraoperative Hemostasis During Deceased Donor Renal Transplant 41 Table 46: Hemopatch - Prospective Randomized Clinical Trial to Prevent Air Leaks After Lung Resection with Hemopatch Sealing Hemostat: SEALLS (Sealing Evaluation of Air Leaks After Lung Surgery) Trial 42 Table 47: Hemopatch - Prospective, Multicenter, Open-label, Randomized, Phase III Clinical Trial of Prevention of Prolonged Air Leak after Lung Resection in High-risk Patients, Applying HEMOPATCH 42 Table 48: Beth Israel Deaconess Medical Center, Inc. Pipeline Products & Ongoing Clinical Trials Overview 43 Table 49: Portable Wound Hemostasis System - Product Status 43 Table 50: Portable Wound Hemostasis System - Product Description 43 Table 51: Biomedica Management Corporation Pipeline Products & Ongoing Clinical Trials Overview 44 Table 52: ClotFoam - Product Status 45 Table 53: ClotFoam - Product Description 45 Table 54: ClotGel - Product Status 46 Table 55: ClotGel - Product Description 46 Table 56: ClotSpray - Product Status 47 Table 57: ClotSpray - Product Description 47 Table 58: Biom'Up SAS Pipeline Products & Ongoing Clinical Trials Overview 48 Table 59: Hemoblast Bellows - Product Status 48 Table 60: Hemoblast Bellows - Product Description 48 Table 61: Cellphire, Inc. Pipeline Products & Ongoing Clinical Trials Overview 49 Table 62: Thromboderm - Product Status 50 Table 63: Thromboderm - Product Description 50 Table 64: Thrombosomes - Hemostatic Agent - Product Status 51 Table 65: Thrombosomes - Hemostatic Agent - Product Description 51 Table 66: Covalent Medical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 52 Table 67: CovaSTAT - Product Status 52 Table 68: CovaSTAT - Product Description 52 Table 69: Covalon Technologies Ltd. Pipeline Products & Ongoing Clinical Trials Overview 53 Table 70: ColActive THP - Product Status 54 Table 71: ColActive THP - Product Description 54 Table 72: CovaStat BioActive Absorbable Hemostatic Sponge - Product Status 55 Table 73: CovaStat BioActive Absorbable Hemostatic Sponge - Product Description 55 Table 74: CryoLife, Inc. Pipeline Products & Ongoing Clinical Trials Overview 56 Table 75: PerClot - Product Status 57 Table 76: PerClot - Product Description 57 Table 77: CryoLife, Inc. - Ongoing Clinical Trials Overview 58 Table 78: PerClot - Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot Polysaccharide Hemostatic System 59 Table 79: Endomedix Incorporated Pipeline Products & Ongoing Clinical Trials Overview 60 Table 80: Internal Hemostat - Product Status 60 Table 81: Internal Hemostat - Product Description 60 Table 82: Topical Hemostat - Product Status 61 Table 83: Topical Hemostat - Product Description 61 Table 84: Entegrion, Inc. Pipeline Products & Ongoing Clinical Trials Overview 62 Table 85: Stasix - Product Status 62 Table 86: Stasix - Product Description 62 Table 87: Ethicon, Inc. Pipeline Products & Ongoing Clinical Trials Overview 63 Table 88: Flowable thrombin - Product Status 63 Table 89: Flowable thrombin - Product Description 63 Table 90: Floralis S.A.S. Pipeline Products & Ongoing Clinical Trials Overview 64 Table 91: Bleeding Controlling Device - Product Status 64 Table 92: Bleeding Controlling Device - Product Description 64 Table 93: Gamma Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 65 Table 94: GammaTF - Product Status 65 Table 95: GammaTF - Product Description 65 Table 96: Haemostatix Limited Pipeline Products & Ongoing Clinical Trials Overview 66 Table 97: HaemoPlax - Product Status 67 Table 98: HaemoPlax - Product Description 67 Table 99: PeproStat - Product Status 68 Table 100: PeproStat - Product Description 68 Table 101: Hemostasis, LLC Pipeline Products & Ongoing Clinical Trials Overview 69 Table 102: ENT Hemostat - Product Status 69 Table 103: ENT Hemostat - Product Description 69 Table 104: Hemostatic Gel - Product Status 70 Table 105: Hemostatic Gel - Product Description 70 Table 106: KeraNetics, LLC Pipeline Products & Ongoing Clinical Trials Overview 71 Table 107: Keratin-Based Hemostat - Product Status 71 Table 108: Keratin-Based Hemostat - Product Description 71 Table 109: LifeBond Ltd. Pipeline Products & Ongoing Clinical Trials Overview 72 Table 110: Absorbable Hemostat - Product Status 72 Table 111: Absorbable Hemostat - Product Description 72 Table 112: LifePatch Heavy - Product Status 73 Table 113: LifePatch Heavy - Product Description 73 Table 114: LifePatch Surgery - Product Status 74 Table 115: LifePatch Surgery - Product Description 74 Table 116: Remedium Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 75 Table 117: Hemogrip Spray-On Foam - Product Status 75 Table 118: Hemogrip Spray-On Foam - Product Description 75 Table 119: Rice University Pipeline Products & Ongoing Clinical Trials Overview 76 Table 120: KOD Hydrogel Hemostat - Product Status 77 Table 121: KOD Hydrogel Hemostat - Product Description 77 Table 122: Samyang Biopharmaceuticals Corporation Pipeline Products & Ongoing Clinical Trials Overview 78 Table 123: B6100 - Product Status 78 Table 124: B6100 - Product Description 78 Table 125: B6102 Hemostatic ORC - Product Status 79 Table 126: B6102 Hemostatic ORC - Product Description 79 Table 127: Sanofi Pipeline Products & Ongoing Clinical Trials Overview 80 Table 128: Lumagel - Product Status 81 Table 129: Lumagel - Product Description 81 Table 130: Sea Run Holdings Inc. Pipeline Products & Ongoing Clinical Trials Overview 82 Table 131: SEA-STAT - Product Status 82 Table 132: SEA-STAT - Product Description 82 Table 133: St Teresa Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 83 Table 134: SURGICLOT - Product Status 83 Table 135: SURGICLOT - Product Description 83 Table 136: WRAPCLOT - Product Status 84 Table 137: WRAPCLOT - Product Description 84 Table 138: St Teresa Medical, Inc. - Ongoing Clinical Trials Overview 85 Table 139: SURGICLOT - A Multicenter Study to Assess the Safety and Performance of SurgiClot in the Treatment of Cancellous Bone Bleeding 86 Table 140: Suneris Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 87 Table 141: VETIGEL - Product Status 87 Table 142: VETIGEL - Product Description 87 Table 143: The Medicines Company Pipeline Products & Ongoing Clinical Trials Overview 88 Table 144: Fibropad Patch - Product Status 89 Table 145: Fibropad Patch - Product Description 89 Table 146: Therus Corporation Pipeline Products & Ongoing Clinical Trials Overview 90 Table 147: Therus Acoustic Hemostasis System - Product Status 90 Table 148: Therus Acoustic Hemostasis System - Product Description 90 Table 149: Xcede Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 91 Table 150: Xcede Patch - Product Status 91 Table 151: Xcede Patch - Product Description 91 Table 152: Glossary 116


List of Figures
Figure 1: Hemostats - Pipeline Products by Stage of Development 10 Figure 2: Hemostats - Pipeline Products by Segment 11 Figure 3: Hemostats - Pipeline Products by Territory 12 Figure 4: Hemostats - Pipeline Products by Regulatory Path 13 Figure 5: Hemostats - Pipeline Products by Estimated Approval Date 14 Figure 6: Hemostats - Ongoing Clinical Trials 15

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecast

Read More...

Global automotive electronics market size forecast is likely to reach USD 279.96 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing application scope of these equipments is estimated to drive industry growth. Increasing i

Read More...

Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to driv

Read More...

Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries s

Read More...

Global glycerol market size is likely to exceed USD 3 billion by 2022, as per a new research report by Radiant Insights, Inc. Regulatory push for promoting bio-diesel production is expected to boost glycerol demand over the forecast period, with expe

Read More...
Choose License Type
Single User - US $4000
Multi User - US $8000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify